Toxicology International (Formerly Indian Journal of Toxicology)

Suraj Singh Yadav , Manish Kumar Singh , Pradeep Dwivedi , Raju Kumar Mandal , Kauser Usman , Sanjay Khattri , Kamlesh Kumar Pant

Abstract

Introduction: A consortium of metabolic risk factors accelerate the onset of diabetes, heart disease, stroke, and certain cancers. Proteolytic enzymes like matrix metalloproteinases (MMP) are regulated by a group of endogenous proteins called tissue inhibitors of metalloproteinases (TIMP). These TIMPs binds to active and alternate sites of activated MMPs and facilitate regulation. Impaired expression of MMPs may have a significant contribution in the pathogenesis of many tissues-destructive processes like tumor progression and cardiovascular and metabolic disorders. Materials and Methods: This case control study lays stress on the possible role of impaired levels of circulating MMP‑2 and 9 in metabolic syndrome (MetS). The age, sex‑matched 388 subjects with 190 newly diagnosed patients, and 198 healthy controls were recruited. To screen the patients with MetS, biochemical analysis of patients for impaired glucose level, hypertension, body mass index (BMI), and lipid profile was performed. The circulating level of MMP‑2 and ‑9 in serum was analyzed by enzyme‑linked immunosorbent assay (ELISA) in all patients and control. Results: All metabolic risk factors were statistically significant (P < 0.01) in patients against control group. The serum MMP‑2 and ‑9 level was significantly higher (P < 0.001) in patients having MetS as compared with control group. Conclusions: Similar trend was observed in gender wise analysis of serum MMP level. Higher MMP level alteration observed in male patients as compared with female patients.

Keywords

Insulin resistance, metabolic syndrome, matrix metalloproteinases‑2, matrix metalloproteinases‑9

Full Text